Symptomatic benign prostatic hyperplasia (BPH), nowadays often referred to as lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO), is a very common condition in elderly men [1] . Due to the ageing of the population, the number of men suffering from LUTS will increase in the next millennium. Whilst about 15% of the population is currently aged 65 years or over, this proportion is expected to increase to 22% (range 19-25%) by 2025 [2] . In addition, these people will live longer and will expect a good quality of life (QoL) and appropriate medical care for the remainder of their (active) life. As a consequence the costs associated with the management of LUTS will increase substantially, whereas healthcare budgets will be relatively restricted. It will thus be a major challenge for the future to improve the cost-effective management of LUTS suggestive of BPO.
Introduction
Symptomatic benign prostatic hyperplasia (BPH), nowadays often referred to as lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO), is a very common condition in elderly men [1] . Due to the ageing of the population, the number of men suffering from LUTS will increase in the next millennium. Whilst about 15% of the population is currently aged 65 years or over, this proportion is expected to increase to 22% (range 19-25%) by 2025 [2] . In addition, these people will live longer and will expect a good quality of life (QoL) and appropriate medical care for the remainder of their (active) life. As a consequence the costs associated with the management of LUTS will increase substantially, whereas healthcare budgets will be relatively restricted. It will thus be a major challenge for the future to improve the cost-effective management of LUTS suggestive of BPO.
Currently, there are considerable differences between the management of LUTS suggestive of BPO across Europe in real life practice (RLP). For example, phytotherapy is particularly popular in France, Germany and Spain, while finasteride is often prescribed in Italy, Poland and the UK. Nevertheless, · 1 -adrenoceptor antagonists are used in all these countries as a primary treatment modality [3] . These differences suggest that the current management of patients is very often more opinion-than evidence-based. A possible explanation for this might be that most evidence available today is based on classical efficacy (related to the effect on symptoms and urinary flow) and safety data of treatments coming from randomised controlled trials (RCTs) conducted on patients treated in secondary care, using protocols with strict inclusion/ exclusion criteria. Consequently the study environment in RCTs does not reflect the patient population in RLP ( fig. 1 ). The major drawback of RCTs is that results can not be readily generalised to clinical practice and as a consequence important questions at initiation of treatment in the real life patient population in primary care remain unanswered, which may at least partly explain the observed differences in prescribing/treatment behaviour seen across Europe. In the near future, more comparative Chapple information is needed on the effectiveness of medical treatments in the long-term in order to allow us to develop specific hypotheses for evidence-based medicine (EBM) in RLP. It is well known that the effectiveness of treatment (i.e. reduction of complications related to BPO and switch to other medical therapy or surgery) is the major cost-driver in the management of LUTS suggestive of BPO.
Evidence-Based Medicine in LUTS
Bearing in mind the ageing of the population and the relatively restricted healthcare budgets, EBM will play a key role in improving cost-effective management of LUTS suggestive of BPO. EBM involves turning clinical problems into precise questions and then systematically locating, appraising and using contemporaneous research findings as the basis for formulating clinical decisions [4] [5] [6] . In urological practice, the available evidence should be reviewed by examining the strength of the published studies with reference to their efficacy and long-term effectiveness. In addition, bothersomeness and impact of treatment on QoL are also very important from a patient's perspective. Consequently, the decision to treat patients should be based on the extent to which symptoms interfere with daily life activities and therefore, QoL measures should be included in all new research studies. Finally, it is important that studies should evaluate both the direct and indirect costs of treatments. It must be remembered that the most costly aspect of any treatment is its failure rate and the need for re-treatment. Although an earlier consensus meeting on BPH in Paris [7] has recommended that all research papers on LUTS secondary to BPH should contain cost-effectiveness data, a review of the recent literature shows that this recommendation has not been implemented by most authors.
Based on the currently available evidence, transurethral resection of the prostate (TURP) remains the most effective treatment for de-obstructing patients, but the technique is less attractive from a patient's point of view [8] . Appropriate long-term data are still required to allow us to determine the ultimate position of most of the new, less invasive surgical techniques. Since medical therapy with either finasteride or · 1 -adrenoceptor antagonists is not invasive as compared to surgery, this type of treatment is popular among patients. Both finasteride and · 1 -adrenoceptor antagonists have a good efficacy and tolerability and are in the 'shorter' term more cost-efficient than TURP [9] . The use of finasteride has been suggested to be best restricted to patients with enlarged prostates (140 ml) [10] , while the efficacy of · 1 -adrenoceptor antagonists is not dependent on prostate size [11] [12] [13] . Among the · 1 -adrenoceptor antagonists, tamsulosin is now widely used and is the market leader as it has good tolerability and is safe with minimal cardiovascular effects and is easy to use (once daily administration without the need for stepwise dose increments on treatment initiation) [14, 15] .
European Panel Study: Appropriateness of Therapy for LUTS
Widespread acceptance of EBM has been the stimulus for several organisations to develop practice guidelines, of which those of the AHCPR and the WHO are the most comprehensive and widely known [16, 17] . However, there still remains a large grey area of treatment choice in which no conclusive evidence exists on the right treatment for every patient. In this situation, the doctor's personal experiences, individual biases and training all act to complement evidence-based guidelines. By applying the RAND/UCLA method [18] , the potential use of expert opinions in further guideline development for LUTS treatment has been assessed. The methodological background to this will be described in more detail by Stoevelaar et al. further on in this supplement [19] . Both a European panel and a Dutch panel rated the appropriateness of commonly available LUTS treatments for a large number of hypothetical patients. It appeared that both panels rated 84% of the indications identically. When no previous treatment was given, an · 1 -adrenoceptor antagonist was considered to be the appropriate initial treatment in more than half of the cases. For cases in which · 1 -adrenoceptor antagonist treatment failed, surgery was most frequently reported to be the appropriate therapy. Finasteride was considered inappropriate in a large number of cases, mainly in patients with small prostate volumes. It is encouraging that these observations are in accordance with the available evidence on the efficacy/tolerability ratio.
Long-Term Effectiveness of Treatments
Although LUTS suggestive of BPO progresses slowly, overall there is a slow background deterioration [20, 21] . Therefore in the management of LUTS it is not only important to consider the efficacy of treatment, but also the effectiveness of treatment in the longer-term. In particular, from a cost-effectiveness point of view it is very important to know how many patients develop complications due to BPO (e.g. AUR) or switch to other medical therapy or surgery. More information on these aspects is needed since these are the major cost-drivers in the management of LUTS suggestive of BPO [22] .
The incidence of AUR during watchful waiting or in placebo arms of clinical trials is low, ranging between 0.5 and 3%/year, dependent on symptom severity and whether the study was community (0.7%/year) [23] or urologists' office based (1-2.5%/year) [24, 25] . Therefore, a large number of patients is needed to evaluate whether medical treatment can prevent the occurrence of AUR. Data from the PLESS study [26] demonstrate that finasteride treatment reduced the risk for AUR (from 7 to 3%) and surgery (from 10 to 5%). Whether · 1 -adrenoceptor antagonists can also reduce the incidence of AUR or need for surgery has not been as intensively studied. One of the reasons for this might be that · 1 -adrenoceptor antagonists, compared to finasteride, have a very fast onset of action (relief within 2-4 weeks) and consequently most trials with · 1 -adrenoceptor antagonists have a relatively short follow-up (3-12 months). The direct comparative studies however indicate that · 1 -adrenoceptor antagonists appear to have at least as positive an effect on disease progression as finasteride [11, 12] . A recently published 6-month study of 1,784 patients in an open study of tamsulosin demonstrated an incidence of AUR that was no higher than those values reported for finasteride [27] .
The 'Medical Therapy of Prostatic Symptoms' (MTOPS) study, which is currently still ongoing, will hopefully allow us to retrieve more information on the impact of medical therapy on disease progression. This study should also be able to clarify whether long-term ·-blockade results in the same risk reduction for AUR and surgery as finasteride. First results can be expected by the end of 2002 [28] .
Triumph: Management of LUTS in RLP
The major shortage of available evidence today, both from an efficacy and effectiveness point of view, is due to the fact that all of these data are obtained in a secondary care setting and from RCTs. Therefore, the results are not easily generalisable to RLP where LUTS are managed by primary care physicians. In order to retrieve more information on cost-effectiveness of initial treatment modalities in real life primary care practice, the Triumph (Transeuropean Research Into the Use of Management policies for LUTS suggestive of BPH in Primary Healthcare) project was established. This project will initially run in 6 European countries: France, Germany, Italy, Poland, Spain and the UK. The project has begun with an analysis of available general practice databases in France (THALES), The Netherlands (IPCI) and the UK (GPRD) to retrieve more information on both the incidence and prevalence of LUTS, its initial management and related long-term treatment failure. In addition, a prospective, cross-sectional, non-interventional survey will run in all 6 countries. Both newly diagnosed (n = 7,480) and existing patients, diagnosed with LUTS suggestive of BPO from January 1997 onwards (n = 5,480), will be prospectively followed for at least 1 year. Baseline characteristics (including I-PSS score), initial treatment choice and events related to disease progression will be collected. For the existing patients up to 3 years retrospective data concerning initial treatment, therapy switches and complications due to BPO will be retrieved from the patient medical records.
In order to assess the costs related to the management of LUTS, health-economists will develop a country-specific costing database for each of the participating countries [29] . These databases will contain estimates of the costs related to visits, investigations, medication, surgery, etc. This can be linked to data on patient characteristics and symptomatology at baseline and during follow-up to allow a cost-effectiveness analysis. In addition, a draft model will be developed based on the GPRD data that will enable, in combination with the national costing databases, country-specific health-economic analyses. This will be fine-tuned once the data from the observational survey become available. Finally, disease states will be developed and validated based on the I-PSS questionnaire that will enable quality adjusted life years (QALY's) calculation based on the I-PSS data collected in the prospective, observational survey. In a QALY-analysis, life years of a patient are 'corrected' for the value of quality of life, which usually varies from 0 (QoL equal to death) to 1 (QoL equal to normal health). In the Triumph project, QALYs are derived by converting health states of the I-PSS into QoL values based on the 'time trade-off' procedure. The validity of this method was initially tested on 100 male and female students. The students ranged the QoL-values from 0.83 for the worst LUTS-state to 0.96 for the best LUTS-state. Furthermore, the factor 'irritative' seemed to be rated as more severe than the factor 'obstructive', which is in line with literature data [30] . In a next step, the ratings of the general public were collected.
After completion of the analysis of these data, a final set of values specific for LUTS suggestive of BPO will be available, which can then be used in economic analyses within the Triumph project [29] .
Triumph: Preliminary Results of the GPRD Study
Analysis of more than 60,000 older men included in the GPRD confirmed that the incidence and prevalence of LUTS increases with age. For the first time a linear relation was demonstrated. Furthermore, the incidence of prostatectomy also increased linearly from the age of 50 to 80 years, with a rate of 15 per 1,000 men at the age of 80. In the UK, the prescription of medical therapies has increased considerably over the last years and they are used earlier. This is probably a good tendency as the GPRD shows that patients receiving medical therapy have surgery at a later stage than patients initially receiving watchful waiting. Moreover, it appears that newer drugs, such as finasteride, alfuzosin and tamsulosin, are not only increasingly used, but are also associated with less treatment failure (i.e. less switch to other therapy, including surgery and less catheterisation) than older treatments such as indoramin and prazosin [31] . The prospective observational survey should act to confirm or refute these observations and will also give us insight into methodological biases such as possible confounding by indication, since in this study information on disease severity is collected at baseline through the I-PSS. Furthermore, for the first time this project will provide us with accurate data on real life practice, answering such questions as to how long individual patients stay on any particular therapy, which therapy, and how often they switch between therapies or progress on to surgery from medical therapy.
Conclusions
Due to the ageing and longevity of the population and the relatively restricted healthcare budgets, more rational management of LUTS suggestive of BPO is needed in the near future. In the framework of this, EBM is very important and should not only be based on efficacy and safety data from RCTs, but also on effectiveness of treatment as assessed in real life practice. Since there appears to be a shift in the initial management from secondary to primary care, more and better studies are needed in real life primary care practice. The Triumph project is one such attempt which will hopefully provide basic data and clinical directions which will enable us to improve the management of LUTS in the future.
